酪氨酸激酶抑制剂抑制非小细胞肺癌脑转移被引量：1

Tyrosine Kinase Inhibitors Suppress Brain Metastases in Advanced Non-small Cell Lung Cancer

导出

摘要 [目的]评价酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKI）对控制脑转移的作用。[方法]83例Ⅳ期（或复发）非小细胞肺癌（NSCLC）患者接受吉非替尼或厄洛替尼治疗,同期67例化疗患者作为对照,随访脑转移出现的时间和生存时间。[结果]经中位11.4个月的随访,TKI组脑转移发生率低于化疗组（18.29%vs 35.38%,χ2=5.5,P=0.019）。TKI组中发生脑转移的中位时间为7.6个月（6.9~8.3个月）,明显长于单纯化疗组4.9个月（4.4~5.4个月）（χ2=15.6,P=0.001）。TKI组中位总生存时间为11.4个月（95%CI：10.3~12.6）,长于单纯化疗组的7.5个月（95%CI：6.6~8.5）（χ2=19.3,P〈0.001）。[结论]TKI降低晚期NSCLC患者脑转移的风险,延长患者的生存时间。 [Purpose] To investigate the effect of tyrosine kinase inhibitors on brain metastasis in patients with advanced non-small cell lung cancer. [Methods] Eighty-three patients with stageⅣ NSCLC treated with gefitinib or erlotinib and 67 patients treated with chemotherapy as control group were collected. The survival time and the time to brain metastasis were analyzed.[Results]With a median follow-up of 11.4 months,the rate of brain metastasis in TKI group was lower than that in chemotherapy group（18.29% vs 35.38%,χ2=5.5,P=0.019）. The median time to brain metastasis in TKI group was 7.6 months（95%CI：6.9~8.3）,which was longer than that in chemotherapy group（4.9months,Log Rank χ2=15.6,P0.001）. The median overall survival time in TKI group was also longer than that in chemotherapy group（11.4 vs 7.5 months,χ2=19.3,P0.001）. [Conclusions] TKI（gefitinib or erlotinib） treatment reduces risk of BM and prolongs survival in patients with advanced NSCLC.

作者严爽王礼吴月兵胡胜

机构地区湖北省肿瘤医院通城县人民医院

出处《中国肿瘤》 CAS 2013年第11期918-921,共4页 China Cancer

基金武汉市重点攻关项目(201161038347)

关键词肺癌脑转移酪氨酸激酶抑制剂 lung cancer brain metastasis tyrosine kinase inhibitors

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献11

1Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with ad- vanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008,26(21):3543-3551.
2Chen AM,Jahan TM,Jablons DM,et al. Risk of cerebral metastases and neurological death after pathological com- plete response to neoadjuvant therapy for locally advanced non-small cell lung cancer:clinical implications for the subsequent management of the brain[J]. Cancer,2007,109 (8): 1668-1675.
3Rosell R, Moran T,Queralt C,et al. Screening for epider- mal growth factor receptor mutations in lung cancer[J]. N Engl J Med,2009,361(10):958-967.
4Maemondo M,Inoue A,Kobayashi K,et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med,2010,362(25):2380-2388.
5Wu C ,Li YL,Wang ZM,et al. Gefitinib as palliative therapy for lung adenoearcinoma metastatic to the brain [J]. Lung Cancer, 2007,57(3):359-364.
6Kim JE,Lee DH,Choi Y,et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis[J]. Lung Can- cer, 2009,65(3):351-354.
7Berger LA ,Riesenberg H ,Bokemeyer C ,et al. CNS metas- tases in non-small-cell lung cancer:current role of EGFR- TKI therapy and future perspectives[J]. Lung Cancer, 2013,80(3):242-248.
8Heon S,Yeap BY, Britt GJ,et al. Development of central nervous system metastases in patients with advanced non- small cell lung cancer and somatic EGFR mutations treat- ed with gefitinib or erlotinib[J]. Clin Cancer Res,2010, 16 (23):5873-5882.
9Kim ST,Lee J,Kim JH,et al.Comparison of gefitinib ver- sus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy[J]. Cancer, 2010,116 (12):3025-3033.
10Gaspar LE,Chansky K,Albain KS,et al. Time from treat- ment to subsequent diagnosis of brain metastases in stage Ⅲ non-small-cell lung cancer:a retrospective review by the Southwest Oncology Group[J]. J Clin Oncol,2005,23 (13):2955-2961.